New therapies for treatment of rheumatoid arthritis.

By J. Smolen, Daniel Aletaha, M. Koeller, M. Weisman, P. Emery. The Lancet, 2007

1,029 citations recorded by the source corpus.

Subfields: Genetics, Radiology, Nuclear Medicine and Imaging, Rheumatology

View Paper: https://www.semanticscholar.org/paper/533bf8a9569bc19eabba00b3d926ea2c1ca5f88c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Martina Anzaghe
2. Yen-Ju Lin
3. S. Schülke
4. J. Smolen
5. K. Redlich
6. C. Gabay

In Radiology, Nuclear Medicine and Imaging

1. J. Smolen
2. I. McInnes

In Rheumatology

1. Daniel Aletaha
2. J. Smolen
3. Martina Anzaghe
4. Yen-Ju Lin
5. S. Schülke
6. I. McInnes
7. S. Gaffen

Citations in the corpus

• Treating rheumatoid arthritis to target: recommendations of an international task force (2010, positive): “Second, the definition of core set variables and development of composite measures to assess RA has allowed disease activity to be assessed reliably.”
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010, positive): “(1) Synthetic DMARDs early— The task force was unanimous in its view that in the vast majority of patients with RA the fi rst treatment approach should include synthetic DMARDs, since a signifi cant proportion of patients can attain a state of very low disease activity or remission36–39; the types o”
• Inflammatory bone loss: pathogenesis and therapeutic intervention (2012, background): “Effective treatment will halt the progression of joint damage, either by reaching remission with chemical disease-modifying antirheumatic drugs such as methotrexate, sulphasalazine or leflunomide, or by using TNF blockers in combination with methotrexat”
• Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis (2020, background): “Therefore, besides activation of resident and infiltrating immune cells, joint inflammation in RA is also characterized by a specific tissue response in which local fibroblasts assume an aggressive pro-inflammatory phenotype characterized by matrix regulatory, osteoclast-generating, and invasive pro”
• 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative (2010, neutral): “the presence of autoantibodies, such as rheumatoid factor (RF) and anti–citrullinated protein antibody (ACPA) (tested as anti–cyclic citrullinated peptide [antiCCP]), which can precede the clinical manifestation of RA by many years (6–9), RA is considered an autoimmune disease (10,11).”
• Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, background): “RA is an autoimmune disease that results in chronic, progressive inflammatory disorders of the joints and surrounding tissues, often leading to irreversible joint damage and systemic complications (Smolen et al., 2007).”
• Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients (2008, background): “Introduction Rheumatoid arthritis (RA) is a systemic autoimmune disorder that is characterized by chronic inflammation of synovial tissue, which results in irreversible joint damage [1].”
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010, positive): “The management of rheumatoid arthritis (RA) rests on several principles. Drug treatment, which comprises disease-modifying antirheumatic drugs (DMARDs), but also non-steroidal anti-inflammatory drugs and glucocorticoids (GCs), as well as non-pharmacological measures, such as physical, occupational a”